RxDoctor Payments Data

Brian Planchard, MD

Ophthalmology · Fort Walton Beach, FLNPI 1639377096

Payments from drug & device makers

$2,447in general payments, 2019–2025

Across 58 payments — averaging $42.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$413
  • Kala Pharmaceuticals, Inc.$378
  • Bausch & Lomb Americas Inc.$350
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$257
  • Amgen$151
  • Ivantis, Inc$126
  • plus $773 from 14 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$2,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,447 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$96,955
Medicare patients
348
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$12,581
LumiganBimatoprost13$6,427
SimbrinzaBrinzolamide/Brimonidine Tart17$3,348
Doxycycline Hyclate26$2,113
Prednisolone Acetate39$1,192
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,056
Latanoprost79$928
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat49$903
MoxifloxacinMoxifloxacin Hcl25$820
ValacyclovirValacyclovir Hcl15$586
Brimonidine Tartrate23$452
Timolol Maleate24$192
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$126$19,00825 claims
AlconSimbrinza$413$3,34817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Fort Walton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →